Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Aspart 30 vs 50 Twice Daily in Type 2 Diabetes
ChiCTR-IIR-16008958Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: HbA1c. Planned start Jun 2016; status: not yet recruiting.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IIR-16008958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008958.